Alteplase for Acute Ischemic Stroke at 4.5 to 24 Hours: The HOPE Randomized Clinical Trial

发布时间：2025-09-01 22:44

'Apology'用'My apologies for the delay'致歉 #生活技巧# #职场沟通技巧# #商务英语口语#

Actions

. 2025 Aug 7:e2512063.

doi: 10.1001/jama.2025.12063. Online ahead of print.

Yaode He 1 2 , Bruce C V Campbell 3 , David S Liebeskind 4 , Changzheng Yuan 5 6 , Hui Chen 5 , Yanxing Zhang 7 , Tingyu Yi 8 , Zhongyu Luo 1 , Zuowen Zhang 9 , Changcai Meng 10 , Jianhua Cheng 11 , Hezhong Ouyang 12 , Jin Hu 13 , Fei Wang 14 , Sheng Zhang 15 , Qi Fang 16 , Haitao Hu 1 2 , Xuting Zhang 1 2 , Yi Chen 1 2 , Wansi Zhong 1 2 , Maarten G Lansberg 17 , Shenqiang Yan 1 2 , Min Lou 1 2 ; HOPE investigators

Collaborators, Affiliations

PMID: 40773205 PMCID: PMC12332759 (available on 2026-02-07) DOI: 10.1001/jama.2025.12063

Alteplase for Acute Ischemic Stroke at 4.5 to 24 Hours: The HOPE Randomized Clinical Trial

Ying Zhou et al. JAMA. 2025.

Abstract

Importance: The safety and efficacy of intravenous thrombolytics beyond 4.5 hours after ischemic stroke onset remain inadequately studied.

Objective: To evaluate the safety and efficacy of intravenous alteplase administered 4.5 to 24 hours after stroke onset in patients with salvageable brain tissue, regardless of the presence of large vessel occlusion.

Design, setting, and participants: This randomized, open-label, blinded end-point trial was conducted at 26 stroke centers across China. A total of 372 patients with acute ischemic stroke and salvageable brain tissue identified by perfusion imaging were enrolled between June 21, 2021, and June 30, 2024 (final follow-up October 2, 2024). Eligibility criteria included stroke onset (or the midpoint between last known well and symptom recognition if onset was unknown) of 4.5 to 24 hours prior to presentation, and no initial plan for endovascular thrombectomy. Data were analyzed from December 2024 to February 2025.

Interventions: Patients were randomly assigned (1:1) using a minimization algorithm to receive intravenous alteplase (0.9 mg/kg; maximum dose, 90 mg; n = 186) or standard medical treatment (n = 186).

Main outcomes and measures: The primary efficacy outcome was functional independence, defined as a modified Rankin Scale score of 0 to 1 at 90 days. Safety outcomes included symptomatic intracranial hemorrhage within 36 hours and all-cause mortality within 90 days.

Results: Among 372 patients who were enrolled (median [IQR] age, 72 [64-80] years; 160 [43%] women), all completed the trial. The primary outcome occurred in 75 of 186 patients (40%) in the alteplase group and 49 of 186 (26%) in the control group (adjusted risk ratio, 1.52 [95% CI, 1.14-2.02]; P = .004; unadjusted risk difference, 13.98% [95% CI, 4.50%-23.45%]). The incidence of symptomatic intracranial hemorrhage was higher with alteplase at 3.8% compared with 0.51% with standard treatment (adjusted risk ratio, 7.34 [95% CI, 1.54-34.84]; P = .01; unadjusted risk difference, 3.23% [0.28%-6.19%]), and mortality was 11% in both groups (adjusted risk ratio, 0.91 [95% CI, 0.52-1.62]; P = .76; unadjusted risk difference, 0% [95% CI, -6.30% to 6.30%]).

Conclusions and relevance: In patients with acute ischemic stroke with salvageable brain tissue identified by perfusion imaging who did not initially receive thrombectomy, intravenous alteplase administered 4.5 to 24 hours after onset provided functional benefit, despite an increase in symptomatic intracranial hemorrhage.

Trial registration: ClinicalTrials.gov Identifier: NCT04879615.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Liebeskind reported support from Cerenovus, Genentech, Medtronic, Stryker, and Rapid Medical for the imaging core lab outside the submitted work. Dr Lansberg reported grants from National Institutes of Health/National Institute of Neurological Disorders and Stroke during the conduct of the study; personal fees from Genentech/Roche outside the submitted work. Dr Lou reported grants from National Natural Science Foundation of China and grants from the Second Affiliated Hospital of Zhejiang University, School of Medicine during the conduct of the study. No other disclosures were reported.

Similar articles

Endovascular thrombectomy with versus without intravenous thrombolysis for acute ischaemic stroke.

Gottlieb M, Carlson JN, Westrick J, Peksa GD. Gottlieb M, et al. Cochrane Database Syst Rev. 2025 Apr 24;4(4):CD015721. doi: 10.1002/14651858.CD015721.pub2. Cochrane Database Syst Rev. 2025. PMID: 40271574

Intra-arterial Tenecteplase for Acute Stroke After Successful Endovascular Therapy: The ANGEL-TNK Randomized Clinical Trial.

Miao Z, Luo G, Song L, Sun D, Chen W, Yao X, Pan Y, Liu Y, Yuan G, Wen C, Wei M, Cai X, Yang Q, Zhou Z, Chang M, Nan G, Wang J, Xiang G, Zhou L, Gao W, Zhang H, Hao J, Xu C, Sun Y, Yi T, Feng G, Han H, Gao F, Ma N, Mo D, Sun X, Deng Y, Tong X, Li X, Jia B, Wang B, He Z, Yang M, Zhao X, Zhang X, Zhang L, Li S, Tong X, Jing J, Xiong Y, Liu T, Li Z, Ren Z, Wang Y, Liebeskind DS, Jovin TG, Nguyen TN, Wang Y, Liu L, Yan B, Huo X; ANGEL-TNK Investigators. Miao Z, et al. JAMA. 2025 Aug 19;334(7):582-591. doi: 10.1001/jama.2025.10800. JAMA. 2025. PMID: 40616323 Clinical Trial.

Tirofiban on First-Pass Recanalization in Acute Stroke Endovascular Thrombectomy: The OPTIMISTIC Randomized Clinical Trial.

Lin L, Liu F, Yi T, Zhu Y, Yang J, Zhao Y, Wang F, Xiang G, Chen C, Xiao Y, Shen H, Xu L, Long Y, Zhang Y, Huang Z, Chen C, Churilov L, Parsons MW, Chen W, Li G; OPTIMISTIC Investigators. Lin L, et al. JAMA Netw Open. 2025 Apr 1;8(4):e255308. doi: 10.1001/jamanetworkopen.2025.5308. JAMA Netw Open. 2025. PMID: 40244586 Free PMC article. Clinical Trial.

Intra-Arterial Tenecteplase Following Endovascular Reperfusion for Large Vessel Occlusion Acute Ischemic Stroke: The POST-TNK Randomized Clinical Trial.

Huang J, Yang J, Liu C, Li L, Yang D, Guo C, Zeng G, Song J, Ma J, Xu X, Shi X, Yang S, Sun W, Wang Z, Tang Y, Jiang M, Wang L, Cheng X, Luo J, Zhou P, Fang X, Cheng G, Ruan Z, Li J, Liu J, Lei B, Tian Y, Tan X, Yuan G, Wang J, Huang X, Deng S, Jin Z, Zou X, Zhang J, Cheng D, Luo X, Liao J, Miao J, Li Z, Sun Y, Jiang G, Kong D, Jiang S, Wang Z, Wang D, Kaesmacher J, Nguyen TN, Nogueira RG, Saver JL, Chen Y, Zi W; POST-TNK Investigators. Huang J, et al. JAMA. 2025 Feb 18;333(7):579-588. doi: 10.1001/jama.2024.23466. JAMA. 2025. PMID: 39804681 Free PMC article. Clinical Trial.

Thrombolysis for acute ischaemic stroke.

Wardlaw JM, Zoppo G, Yamaguchi T, Berge E. Wardlaw JM, et al. Cochrane Database Syst Rev. 2003;(3):CD000213. doi: 10.1002/14651858.CD000213. Cochrane Database Syst Rev. 2003. PMID: 12917889 Updated.

References

Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50(12):e344-e418. doi: 10.1161/STR.0000000000000211 - DOI - PubMed Berge E, Whiteley W, Audebert H, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur Stroke J. 2021;6(1):I-LXII. doi: 10.1177/2396987321989865 - DOI - PMC - PubMed Hacke W, Kaste M, Bluhmki E, et al. ; ECASS Investigators . Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317-1329. doi: 10.1056/NEJMoa0804656 - DOI - PubMed Tong D, Reeves MJ, Hernandez AF, et al. Times from symptom onset to hospital arrival in the Get with the Guidelines–Stroke Program 2002 to 2009: temporal trends and implications. Stroke. 2012;43(7):1912-1917. doi: 10.1161/STROKEAHA.111.644963 - DOI - PubMed Ma H, Campbell BCV, Parsons MW, et al. ; EXTEND Investigators . Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke. N Engl J Med. 2019;380(19):1795-1803. doi: 10.1056/NEJMoa1813046 - DOI - PubMed